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Background: The role of anxiety and depression in the physical activity (PA) of patients 
with COPD is controversial. We prospectively assessed the effect of symptoms of anxiety and 
depression on PA in COPD patients.
Methods: We evaluated anxiety and depression (Hospital Anxiety and Depression Scale 
[HADS]), PA (Dynaport® accelerometer), and other relevant characteristics in 220 COPD 
patients from five European countries at baseline and at 6 and 12 months of follow-up. HADS 
score was categorized as: no symptoms (score 0–7), suggested (8–10), and probable (.11) 
anxiety or depression. We estimated the association between anxiety and depression at t (base-
line and 6 months) and PA at t+1 (6 and 12 months) using regression models with a repeated 
measures approach.
Results: Patients had a mean (standard deviation) age of 67 (8) years, forced expiratory volume 
in 1 second 57 (20)% predicted. At baseline, the prevalence of probable anxiety and depression 
was 10% and 5%, respectively. In multivariable models adjusted by confounders and previous PA, 
patients performed 81 fewer steps/day (95% confidence interval, -149 to -12, P=0.02) per extra 
point in HADS-depression score. HADS-anxiety symptoms were not associated with PA.
Conclusion: In COPD patients, symptoms of depression are prospectively associated with a 
measurable reduction in PA 6 months later.
Keywords: COPD, anxiety, depression, HADS, physical activity, prospective study
Introduction
The determinants of physical activity (PA) in patients with COPD are poorly 
understood. A recent systematic review identified several clinical, functional, socio-
demographic, and lifestyle factors associated with PA in these patients, but the quality 
of evidence was low to very low, mainly due to the use of a cross-sectional design 
and lack of control for confounders. This lack of information is in contrast with the 
importance of PA in COPD, as regular PA has been consistently related to a reduced 
risk of hospitalizations and death.1
Among the potential determinants of PA that can be modified at the clinical setting, 
anxiety and depression are relevant because they are highly prevalent in COPD patients 
and affect COPD prognosis.2–4 Anxiety has been reported in ∼40% of COPD patients.5 
It can lead to tachypnea, which may worsen lung hyperinflation, leading to increased 
exertional dyspnea, reduced exercise capacity, and poor quality of life.6 Depression, 
in turn, has been identified in ∼25% of COPD patients5 and is also associated with 
poorer exercise capacity and worse health status.2
Previous studies have assessed the association between anxiety and depres-
sion symptoms with PA.7–15 However, they have a cross-sectional design so the 
directionality of the association (eg, whether anxiety/depression reduces PA or 
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PA reduces anxious/depressive symptoms) could not be 
established. Moreover, prior analyses have not considered 
the role of potentially relevant confounders, like exercise 
capacity9,11,12,15,16 or smoking status.7–11,13 Hence, it remains 
unclear if anxiety or depression exerts an independent effect 
on PA levels alongside other factors commonly influencing 
these levels. Finally, most studies mentioned7–9,12,14,15 used 
indirect measures of PA such as questionnaires, so there is 
potential for misclassification of the primary outcome of 
interest (ie, PA).17
We therefore aimed to assess the effect of anxiety 
and depression symptoms on PA in patients with COPD, 
overcoming the limitations of previous studies by using a 
prospective design, measuring PA with an accelerometer 
and controlling for a wide range of potential confounders. 
We hypothesized that symptoms of anxiety and depression 
are inversely related with future PA in COPD patients. This 
study is part of the “Physical Activity as a Crucial Patient 
Reported Outcome in COPD (PROactive)” project.
Methods
See complete version in the Supplementary material.
Design
Prospective study, with repeated measures at baseline, 
6 months, and 12 months. Clinical trial registration: www.
clinicaltrials.gov; number: NCT01388218.
study population
Between July 12th and November 18th, 2011, we recruited 
a consecutive sample of 236 patients with COPD defined by 
spirometry (post-bronchodilator forced expiratory volume in 
1 second to forced vital capacity ratio [FEV
1
/FVC] ,0.70), 
and followed them for 1 year with visits at baseline and 
at 6 and 12 months. Patients were recruited from tertiary 
hospitals, rehabilitation centers, and primary care settings 
from Athens (Greece), Edinburgh and London (UK), Leuven 
(Belgium), and Groningen (the Netherlands). Inclusion cri-
teria were: i) men or women at least 40 years of age, ii) with 
medical diagnosis of COPD (FEV
1
/FVC less than 70%) 
confirmed by spirometry, iii) smoking history equivalent to 
at least 10 pack years, and iv) able to read and write and to 
use electronic devices and PA monitors. Exclusion criteria 
were: i) orthopedic, neurological or other complaints that 
significantly impair normal biomechanical movement pat-
terns, ii) respiratory diseases other than COPD (eg, asthma), 
and iii) cognitive impairment; further details on inclusion 
and exclusion criteria have been reported elsewhere.18 
For the current study we additionally excluded patients who 
at baseline had a clinical diagnosis and/or active treatment 
for anxiety or depression (n=16). Thirty-seven patients were 
lost to follow-up; there were no baseline differences between 
patients followed and lost to follow-up except for a lower 
frequency of cardiovascular diseases in those lost to follow-up 
(32.4% vs 57.9%, P-value =0.05) (Table S1). No patients were 
diagnosed with anxiety or depression during follow-up.
This study was conducted in accordance with the amended 
Declaration of Helsinki, advised and approved by the PRO-
active ethics and patient advisory boards, approved by local 
institutional review boards (Commissie Medische Ethiek 
van de Universitaire Ziekenhuizen KU Leuven; Medische 
Ethische Toetsingscommissie Universitair Medisch Centrum 
Groningen; Lothian Ethics Committee; South East Scotland 
Research Ethics Committee; Scientific Council of the General 
Hospital for Chest Diseases, Sotiria), and written informed 
consent was obtained from all patients.
Measurements
At baseline, we collected age, sex, ethnicity, marital status, 
living status, socio-economic status, and working status. 
Anxiety and depression symptoms were evaluated at baseline 
and at 6 months, using the linguistically and culturally vali-
dated versions of the Hospital Anxiety and Depression Scale 
(HADS)19 that provides a HADS-depression (HADS-D) and 
a HADS-anxiety (HADS-A) score. Both total scores range 
from 0 to 21. According to literature in the field values from 
0 to 7 are considered normal, a score of 8 to 10 is suggestive 
of the presence of the corresponding mood disorder, and a 
score of 11 or higher indicates probable presence of the cor-
responding mood disorder.20
PA was measured at baseline, and at 6 and 12 months 
(mean [standard deviation, SD]) lapse 177 (12) days between 
baseline and 6 months visits, and 179 (14) days between 
6 and 12 months visit, using a validated accelerometer,21,22 
the Dynaport MoveMonitor (McRoberts BV, The Hague, 
the Netherlands). Patients were instructed to wear it at least 
10 hours per day during 7 days. We defined an a priori valid 
activity monitor measurement if patients recorded at least 
3 days per week (not necessarily consecutive) with at least 
10 hours per day, without distinction between weekdays and 
weekends, according to previous literature.23–25 We obtained 
the following variables: wearing time, steps per day, and 
time in locomotion.
We collected additional information at baseline and at 
6 months as detailed in the Supplementary material, briefly, 
smoking history, COPD exacerbations history, dyspnea, qual-
ity of life (COPD assessment test [CAT]), doctor’s diagnosis 
of comorbidities, treatments, body mass index (BMI), fat free 
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mass index, lung function (FEV
1
, FVC, total lung capacity 
[TLC], residual volume [RV], RV/TLC), and exercise capac-
ity (6 minutes walking distance test [6MWD]).
statistical analysis
The number of subjects available was greater than required 
according to sample size calculations (see Supplementary 
material). We assessed the presence and patterns of missing 
values and, assuming the missing-at-random hypothesis (ie, 
missingness conditional on measured patients’ characteristics) 
(see Supplementary material for further detail),26 we used 
multiple imputation (100 imputed datasets) with the method 
of chained equations.27 We compared the characteristics of 
patients in the complete case to the imputed datasets (Table S2). 
All analyses were performed using the imputed dataset.
In order to maximize data use we used a repeated measures 
approach (Figure 1), each patient contributing twice to the 
analysis. Let t denote each time period (baseline, 6 months, 
and 12 months). For each patient, we estimated the association 
between anxiety or depression at t and PA at t+1, ie, anxiety 
or depression at baseline and PA at 6 months, and anxiety or 
depression at 6 months and PA at 12 months, respectively. 
In bivariate and multivariable analyses we accounted for the 
correlation between observations of the same subject.
First, we tested the bivariate associations between anxiety 
and depression (both categorized according to clinically rel-
evant cut-offs20 and as continuous variables) and PA (steps/
day and time in locomotion), using analysis of variance and 
linear regression, given that PA outcomes were normally 
distributed. Prior to building multivariable models we used 
generalized additive model analyses to test whether the shape 
of the association between anxiety or depression and PA 
was linear. Then, we used multivariable linear regression to 
assess the independent effect of anxiety and depression on 
PA. We tested a list of potential confounders according to a 
previous systematic review on determinants of PA in COPD1 
and clinical expertise, including: age, sex, ethnicity, marital 
status, socio-economic status, working status, smoking status 
and intensity, study site, FEV
1
, FVC, TLC, RV, RV/TLC, 
BMI, fat free mass index, dyspnea, 6MWD, total number of 
comorbidities, cardiovascular disease, diabetes, respiratory 
and non-respiratory drug treatment, CAT score, COPD 
exacerbations in the previous year, and season of PA mea-
surement. From these variables, we built a “saturated model”, 
which included: i) variables independently related to the 
exposure or the outcome (P-value ,0.05), or that modified 
(.10% change in coefficient) the estimates for the remaining 
variables and ii) PA at t. As a final step, we built a “parsimo-
nious model” using a backward stepwise elimination process 
from the “saturated model” removing variables (one at a time) 
if Wald’s P-value .0.15.28 We tested goodness-of-fit of the 
final models (Supplementary material).
To identify potential effect modification, we stratified 
main analyses according to sex, health-related quality of life, 
COPD spirometric severity, smoking status, comorbidities, 
exercise capacity, socio-economic status, and BMI (Supple-
mentary material). To test the potential role of COPD exacer-
bations during follow-up as mediators of the effect of anxiety 
or depression on PA, we repeated the analyses: i) including 
“COPD exacerbations during follow-up” as a covariate in 
multivariable models, and ii) excluding patients who had at 
least one COPD exacerbation during the follow-up period.
We performed several secondary analyses (Supplemen-
tary material) to assess the sensitivity of our estimates to our 
assumptions regarding biases, as well as to test for model 
misspecification. Briefly, we repeated analyses: i) using PA 
at 12 months only (ignoring measures at 6 months), ii) addi-
tionally adjusting for season of PA assessment, and iii) using 
complete case dataset. The analyses were performed using 
Stata 12.1 (Stata Statistical Software: Release 12; StataCorp 
LP, College Station, TX, USA) and R 3.0.1 (R Foundation 
for Statistical Computing, Vienna, Austria).
Results
A total of 220 patients were included, distributed similarly 
across study sites (48 [21.8%] from Athens, 41 [18.6%] 
from Edinburgh, 48 [21.8%] from Leuven, 48 [21.8%] 
from London, and 35 [15.9%] from Groningen). A majority 
of patients were men (68%), with a mean (SD) age of 67 
(8) years, FEV
1
 57 (20)% predicted, RV/TLC 51 (11)%, BMI 
27.1 (5.5) kg/m2, and a moderate quality of life (Table 1). 
The baseline prevalence of suggested and probable anxiety 
was 19% and 10% respectively, and the corresponding preva-
lence for depression was 16% and 5%. All followed patients 
had valid (ie, at least 3 days with at least 10 hours wearing 
time) data from the accelerometer. The mean (SD) Dynaport 
wearing time was 880 (120) min/day, the mean number of 
steps was 4,812 (3,147) and mean time in locomotion was 
60 (36) min/day. During follow-up, 22 (10%) patients were 
hospitalized at least once for a COPD exacerbation.
Figure 1 approach to assess the effect of anxiety and depression (exposures) at t and 
physical activity (outcome) at t+1 adjusting for covariates and physical activity at t.
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In bivariate analysis, depression symptoms at t were 
associated with a lower amount of PA at t+1 (6 months 
later) in a linear dose-response shape: 4,752 (2,334), 3,837 
(1,987), and 3,446 (2,144) steps/day in patients with no 
symptoms, suggested and probable depression, respectively, 
P-trend =0.02 (Figure 2 and Table S3). Corresponding 
time in locomotion was 59.2 (37.3), 49.1 (31.5), and 39.8 
(44.1) min/day, P-trend =0.01. The differences of PA across 
HADS-A categories were not statistically significant.
In the multivariable saturated model (adjusted for age, 
6MWD, comorbidities, FEV
1
, and steps at t), patients 
walked 70 steps/day less (P=0.05) for each extra point on the 
HADS-D score (Table 2). This association persisted in the 
parsimonious model (β=-81 steps/day, P=0.02). HADS-D 
score was also significantly associated with less time in 
locomotion (Table S4). HADS-A score was not statistically 
associated with any PA outcome in multivariable models.
The effect of HADS-D on steps did not change after 
stratifying by potential effect modifiers, with two exceptions: 
i) a stronger association among patients with moderate CAT 
scores (β=-132, P=0.03) compared to patients with lower 
or higher CAT scores (β=-19, P=0.79 and β=-26, P=0.73, 
respectively), and ii) a stronger association among people 
with high socio-economic status compared to those with 
low socio-economic status (β=-88, P=0.02, vs -2, P=0.98, 
respectively) (Table S5).
The inclusion of COPD exacerbations during follow-up 
in the model did not modify the estimate of the association 
between depression and steps either (β=-70 steps/day per 
each HADS-D point, P=0.05) (Table S6). Similarly, the 
exclusion of patients with any COPD exacerbation during 
follow up (n=101, 46%) did not modify such estimate (β=-81, 
P=0.15) (Table S6). Sensitivity analyses yielded very similar 
results (Tables S7–S9). Linear regression goodness-of-fit 
tests did not reveal any abnormality.
Discussion
Our study shows that depression symptoms, as measured 
by the HADS, are prospectively associated with fewer steps 
per day and less time in locomotion in COPD patients after 
6 months. However, no effect of anxiety on PA variables 
was found.
Previous studies reported a cross-sectional association 
between depression and PA levels in COPD patients.7–12 Our 
findings move beyond these preliminary findings by testing 
the directionality of this association. Indeed, presence of 
depressive symptomatology very quickly seems to negatively 
impact PA (ie, over a time period of 6 months already), 
even after adjusting for baseline PA levels. Furthermore, 
in contrast to previous studies, our study for the first time 
controlled for a comprehensive set of potential confounders 
such as lung function, exercise capacity or comorbidities. 
Moreover, while previous studies focused on the role of 
depressive disorder, we demonstrated that presence of 
depressive symptoms impacts PA, a finding that is of major 
clinical importance. As each extra point in the HADS-D 
score was associated with a reduction of 81 steps, our results 
support that COPD management includes the assessment 
and treatment of mood disorders, even at subclinical stages. 
We would suggest that further research includes random-
ized controlled trials of drug and non-drug interventions to 
Table 1 Baseline sociodemographic, clinical, and functional 
characteristics of 220 COPD patients from five European sites
Baseline characteristics All patients
n=220
age (years), m (sD) 67 (8)
sex: male, n (%) 149 (68%)
living alone, n (%) 108 (49%)
socio-economic status:a low (IV and V), n (%) 30 (14%)
active worker, n (%) 26 (12%)
smoking status: current, n (%) 38 (17%)
Pack years, median (P25 to P75) 47 (31 to 72) 
any COPD exacerbation in the previous year, n (%) 88 (40%)
mMrC score, median (P25 to P75) 2 (1 to 2)
number of chronic diseases (other than COPD),  
median (P25 to P75)
2 (1 to 3)
Cardiovascular disease,b n (%) 118 (54%)
Diabetes, n (%) 19 (9%)
Musculoskeletal diseases,c n (%) 48 (22%)
Osteoporosis,d n (%) 23 (10%)
Body mass index (kg/m2), m (sD) 27 (5)
Fat free mass index (kg/m2), m (sD) 18 (3)
FeV1 (% predicted), m (sD) 57 (20)
COPD severity stages
I – Mild (FeV1 $80%) 30 (14)
II – Moderate (FeV1 ,80% and $50%) 101 (46)
III – severe (FeV1 ,50% and $30%) 69 (31)
IV – Very severe (FeV1 ,30%) 20 (9)
rV/TlC (%), m (sD) 51 (11)
six minutes walking distance test, m (sD) 423 (130)
CaT score (0 to 40), median (P25 to P75) 14 (8 to 21)
Probable anxiety (haDs-a $11), n (%) 23 (10%)
Probable depression (haDs-D $11), n (%) 12 (5%)
Notes: asocio-economic status was measured through the UK national statistics 
Socio-economic classification. bCardiovascular disease was the presence of doctor-
diagnosed diseases in medical records (ICD9 390–459). cMusculoskeletal diseases 
included connective tissue diseases (ICD9 710–739). dOsteoporosis included 
osteoporosis (ICD9 733.0) and osteopenia (ICD9 733.90).
Abbreviations: m, mean; sD, standard deviation; P25, 25th percentile; P75, 75th 
percentile; mMRC, Modified Medical Research Council Dyspnea Scale; FEV1, forced 
expiratory volume in 1 second; rV/TlC, residual volume to total lung capacity 
ratio; CaT, COPD assessment test; haDs-a, hospital anxiety and Depression 
scale-anxiety; haDs-D, hospital anxiety and Depression scale-Depression; ICD, 
International Classification of Diseases. 
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reduce depression symptoms, since they may be valuable 
also to improve PA.
Several mechanisms have been proposed that support the 
plausibility of depression symptoms affecting PA in both 
COPD and healthy individuals. First, a recent systematic 
review found a clear association between depression and 
hospital admissions caused by COPD exacerbations29 and an 
effect of exacerbations on PA levels has also been reported.30 
However, we could not confirm that the effect of depression 
on PA is mediated by COPD exacerbations. Second, hor-
monal changes that appear during depression, including over-
activity of the hypothalamo-pituitary-adrenocortical axis31 or 
dysregulation of the autonomous nervous system,32,33 have 
been associated with reduced PA in experimental studies34,35 
and deserve further scrutiny in COPD patients. Finally, 
symptoms of depression may exacerbate the perception of 
dyspnea,36 which in turn could reduce PA levels.
The lack of a measurable confounding role of exercise 
capacity in the association between depression and PA in our 
study, together with the large body of evidence showing a 
weak to moderate correlation between exercise capacity and 
daily PA,37 suggests that the clinical effects of depression on 
COPD patients may be underestimated if only controlled 
assessment of exercise capacity is performed at the clinical 
Figure 2 Distribution of steps and time in locomotion at t+1, according to categories of haDs-a and haDs-D at t.
Notes: (A) steps at t+1 across haDs-a categories at t; (B) steps at t+1 across haDs-D categories at t; (C) time in locomotion t+1 months across haDs-a categories 
at t; and (D) time in locomotion at t+1 across haDs-D categories at t. haDs-a score: 0–7 normal, 8–10 suggested anxiety, and $11 probable anxiety. haDs-D score: 0–7 
normal, 8–10 suggested depression, and $11 probable depression.
Abbreviations: haDs-a, hospital anxiety and Depression scale-anxiety; haDs-D, hospital anxiety and Depression scale-Depression.
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or research setting. Further, we found a stronger effect of 
depression on PA among people with moderate impact on 
quality of life than in those with low or high impact on quality 
of life. It could be speculated that patients with a moderate 
quality of life are those who experience the bigger impact of 
depressive symptoms on health outcomes, because in milder 
stages the depression symptoms are lower while in worsened 
quality of life, patients have reached the acceptance of the 
disease together with a higher understanding of their limita-
tions. As previous research has reported a strong relationship 
between depression symptoms and quality of life scores in 
COPD patients,38,39 the interaction between these factors 
on COPD outcomes should be considered both in clinical 
practice and research settings.
The role of anxiety in PA levels is unclear because a 
previous study has found an inverse association (ie, anxiety 
reduces PA level),12 while another study found a positive 
association (ie, anxiety increases PA level).10 Yet, these 
studies suffer from methodological limitations as previ-
ously discussed, including a cross-sectional design, indirect 
measures of PA, and lack of control for confounders. Our 
study, overcoming all the aforementioned limitations, found 
no significant association between anxiety symptoms and PA 
level in COPD patients. Although several studies have pos-
tulated common characteristics between anxiety and depres-
sion, both at molecular40 and clinical levels,41 other studies 
support significant differences between the two. Clinically, 
levels of psychomotor hyperactivity are increased in anxiety42 
but reduced in depression,43 which could lead to differential 
effects on PA. Although elucidating these mechanisms is 
beyond the scope of the present study, our data support the 
need to further research the pathophysiological differences 
between the two entities44 in order to avoid attributing, 
a priori, common effects.
The strengths of our study include the exhaustive control 
for potential confounders, the use of direct methods to assess 
PA, and the longitudinal design. Limitations of our study are 
the following. Information bias in the measure of anxiety and 
depression is possible because the questionnaire is subject 
to potential mis-classification. However, HADS has been 
demonstrated to have good psychometric properties.45,46 
It could be argued that the proportion of patients with HADS 
anxiety and HADS depression $11 was low (10% and 5%, 
respectively) in comparison with other studies.2–4,47–49 This 
can be due to the fact that we excluded patients with a diag-
nosis and/or treatment for clinical depression and/or anxiety 
(to avoid any effect of therapies on PA level). Consequently, 
it is likely that the association between depression and PA 
level is higher in the whole COPD population than in our 
sample. In any case, confirmation of our results in studies 
using other validated instruments to assess anxiety and 
depression is warranted. Secondly, it could be argued that our 
population does not represent the full COPD spectrum and 
so the results cannot be generalized to all patients. However, 
it is worth noting that this risk was mitigated by including 
patients recruited in diverse settings (primary care, hospital, 
and rehabilitation) and a range of mild to very severe air-
flow limitation. Anyhow, any difference in the prevalence 
of depression, anxiety or PA levels with respect to the full 
COPD population would not have affected the association 
between them. Third, reverse causation, ie, that PA affects 
depression symptoms, could have been an alternative inter-
pretation if the study design was cross-sectional. However, 
our study had a longitudinal prospective design, with anxiety 
Table 2 Crude and adjusted associations between haDs-depression score at t and daily steps at t+1 (linear regression model)
Characteristics at t Crudea Adjusted
Saturated modelb Parsimonious modelc
β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value
Constant n/a – 4,690 (4,323 to 5,058) ,0.01 4,733 (4,377 to 5,089) ,0.01
haDs-D (per each extra point) -204 (-313 to -96) ,0.01 -70 (-141 to 0) 0.05 -81 (-149 to -12) 0.02
age (per each extra year old) -86 (-131 to -42) ,0.01 -15 (-50 to 19) 0.37 – –
six minutes walking distance test (6MWD, per 
each extra meter)
11 (8 to 13) ,0.01 1.7 (-0.8 to 4.2) 0.17 – –
$2 comorbidities -984 (-1785 to -182) 0.01 -332 (-833 to 169) 0.19 -414 (-901 to 72) 0.09
FeV1 % predicted (per each extra percent unit) 42 (21 to 63) ,0.01 10 (-3 to 22) 0.13 11 (-0.8 to 23) 0.06
steps/day at t (per each extra step) 0.7 (0.6 to 0.8) ,0.01 0.6 (0.5 to 0.8) ,0.01 0.6 (0.5 to 0.8) ,0.01
Notes: aeach row is a single model. bThe column is a single model. The value of the constant is the number of steps at t+1 of a patient with mean haDs-D score, mean age, 
mean 6MWD, ,2 comorbidities, mean FeV1 (% predicted) and mean steps/day at t. 
cThe column is a single model. The value of the constant is the number of steps at t+1 of 
a patient with mean haDs-D score, ,2 comorbidities, mean FeV1 (% predicted) and mean baseline steps/day at t.
Abbreviations: CI, confidence interval; N/A, not applicable; HADS-D, Hospital Anxiety and Depression Scale-Depression; FEV1, forced expiratory volume in 1 second.
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and depression being measured at baseline, PA measured 
6 months later, and baseline PA having been included as a 
covariate in the regression models to account for PA his-
tory and potential reverse causation. Finally, although the 
possibility of residual confounding can never be ruled out, 
to the authors’ knowledge, all potential confounders were 
collected and tested.
Conclusion
In conclusion, symptoms of depression are prospectively 
associated with a measurable reduction in PA 6 months later 
in COPD patients. Whereupon, and since the current manage-
ment guidelines for patients with COPD include the treatment 
of comorbidities, our study suggests that the management of 
symptoms of depression need to be considered, including in 
subclinical states, to prevent decline in PA over time.
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